

### **Investment Rational:**

NeuroGenesis is a clinical-stage cellular therapy company focused on developing novel and effective treatments for neurodegenerative diseases. The company has established NG-01 as a proprietary method to transform a unique subpopulation of marrow-derived stem cells into bio-factories for sustained delivery of regenerative and neuroprotective proteins. By promoting myelin and neuronal regeneration, the NG-01 technology is optimized to treat neurodegenerative diseases such as progressive multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). NG-01 has been studied extensively in several clinical trials including a successful double blind, randomized, placebo-controlled Phase 2 study for progressive MS, and two long term (up to 4 years) Phase 2a trials for Progressive MS and ALS. To date, more than 160 progressive MS and ALS patients from around the world have been treated with this breakthrough therapeutic modality.

Headquartered in Upstate NY, NeuroGenesis is steadily moving forward with a global, FDA-approved multi-site Phase 2b trial for secondary progressive multiple sclerosis, in partnership with major medical research centers in the United States and abroad.

**Business Strategy** : The company plans to establish several GMP facilities around the world to collect the patient's autologous bone marrow and manufacture NG01 personalized treatments for MS and ALS.

### **Core Technology:**

NG-1 Cell Therapy Platform - URL: [www.neurogenesis-cell.com/ourproducts](http://www.neurogenesis-cell.com/ourproducts)

Description: NG-1 is an autologous bone marrow derived cell product, designed to induce immune modulation and neuro-regeneration.

Development phase: Phase 2b

Clinical Indications: Progressive Multiple Sclerosis, Amyotrophic Lateral Sclerosis

Mech. of Action: secretion of BDNF, CNTF and NFG as well as stimulation of immunomodulation and neuroprotection.

Detailed Product Description: NG-1 has neuroprotective and neuro-regenerative properties. NG-1 can prevent neurons and oligodendrocytes from apoptosis via the release of trophic and anti-apoptotic molecules (NGF, BDNF, and others), and has anti-proliferative effects on microglial cells and astrocytes, resulting in the induction of a neuroprotective microenvironment.

### **Product Profile/Pipeline:**

The FDA recently cleared the Phase 2b trial in Progressive MS. The study will be led by the principal investigator Andrew Goodman, M.D., who was the global lead investigator for the Ampyra trials (the only approved MS drug for walking improvement). Dr. Goodman is currently a Professor of Neurology, Chief of the Neuroimmunology Unit, and Director of the Multiple

Sclerosis Center at the University of Rochester Medical Center. This will be a global clinical trial with sites including the University of Rochester Medical Center (URMC), Mass General, Brigham & Women's Hospital, Columbia University, and Hadassah Medical Center. Each clinical site will be managed by world-renowned MS KOLs.